Cadrenal Therapeutics (CVKD) Expected to Post Earnings on Monday

Cadrenal Therapeutics (NASDAQ:CVKD) is anticipated to release its Q3 2026 resultson Monday, November 9th. Analysts expect Cadrenal Therapeutics to post earnings of ($0.91) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.28. On average, analysts expect Cadrenal Therapeutics to post ($3.86) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Cadrenal Therapeutics Stock Performance

Shares of NASDAQ CVKD opened at $1.01 on Monday. The company has a market cap of $3.60 million, a P/E ratio of -0.20 and a beta of 1.94. The firm’s fifty day moving average is $1.14 and its two-hundred day moving average is $3.97. Cadrenal Therapeutics has a 52-week low of $0.82 and a 52-week high of $13.63.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Cadrenal Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc (NASDAQ: CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients who require long-term anticoagulation. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant designed for individuals with implanted mechanical heart valves and other mechanical circulatory support devices.

Tecarfarin is a vitamin K antagonist intended to address challenges associated with existing anticoagulant therapy, including drug interactions and changes in a patient’s metabolism.